Newsletters

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated continued dependency on ERG in metastatic prostate cancer and identify a druggable pocket within its N-terminal Pointed (PNT) domain.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified ZNF263 as a transcriptional repressor that silences MHC-I by recruiting nucleosome-remodeling and deacetylase (NuRD) to the STAT1 promoter, reducing STAT1 and MHC-I expression.

[Journal for Immunotherapy of Cancer] Scientists hypothesized that the addition of stereotactic body radiation therapy could enhance immune responses and improve treatment outcomes.

[Cancer Letters] The authors functionally characterized a novel docetaxel resistance-associated lncRNA in prostate cancer. They identified an uncharacterized lncRNA, termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues.

[British Journal of Cancer] ATGL-mediated lipolysis represents a promising therapeutic target in prostate cancer, with heightened sensitivity in tumours lacking metabolic flexibility to utilize alternative pathways.

[Oncogene] Researchers showed that the rRNA m6A methyltransferase METTL5 was progressively upregulated during prostate cancer progression and was associated with poor patient survival.

[Cancer Science] Scientists revealed that the nuclear receptor subfamily 3 group C member 1 (NR3C1)-acyl-CoA synthetase long-chain family member 4 (ACSL4) axis regulates lipid peroxidation and promotes radioresistance.

[Journal of Medicinal Chemistry] The authors highlight that PSMA-targeting agents incorporate the O-(carboxymethyl)-L-tyrosine scaffold, a versatile linker that enhances binding affinity and optimizes pharmacokinetics.

[Pfizer, Inc.] Pfizer, Inc. announced that the US FDA accepted for Priority Review a supplemental New Drug Application for TALZENNA^®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI^®, an androgen receptor pathway inhibitor, in men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

[Proceedings of the National Academy of Sciences of the United States of America] The authors systematically deciphered the precise interaction mechanism between SNORD78 and the m⁶A reader IMP2 in colorectal cancer.

[NPJ Precision Oncology] As one of the Cullin RING Ligase 4 adapters, DNA damage-binding protein 1 - and CUL4 correlation factor 13 (DCAF13) appeared strongly expressed in different tumors. Scientists' findings confirm enhanced expression of DCAF13 in tissues of colorectal cance origin and related cell.

[Cell Death & Disease] Researchers showed that extracellular matrix stiffness drives colorectal cancer progression by activating Piezo1-dependent cholesterol synthesis.